Investors

Lophora is funded by BII (Novo Nordisk Foundation), Innovation Fund Denmark, Export and Investment Fund of Denmark (EIFO), family offices and experienced biotech investors such as Don deBethizy (USA) and Tim Haines (UK).

In January 2025, Lophora successfully closed a $3M financing round to advance Phase I trials for its lead CNS drug, LPH-5.

Annual reports and Expanded business information can be found on the Danish Central Business Register.